E. coli biotin ligase
(BirA) is highly specific in covalently attaching biotin to the 15
amino
acid AviTag peptide. This recombinant protein was biotinylated in
vivo
by AviTag-BirA technology, which method is BriA catalyzes amide
linkage
between the biotin and the specific lysine of the AviTag.
The tag type will
be
determined during production process. If you have specified tag
type, please tell us and we will develop the specified tag
preferentially.
產品提供形式:
Lyophilized powder
Note: We will
preferentially ship the format that we have in stock, however,
if you have any special requirement for the format, please
remark your requirement when placing the order, we will prepare
according to your demand.
復溶:
We recommend that this vial be briefly centrifuged
prior
to opening to bring the contents to the bottom. Please reconstitute
protein in deionized sterile water to a concentration of 0.1-1.0
mg/mL.We recommend to add 5-50% of glycerol (final concentration)
and
aliquot for long-term storage at -20℃/-80℃. Our default final
concentration of glycerol is 50%. Customers could use it as
reference.
儲存條件:
Store at -20°C/-80°C upon receipt, aliquoting is
necessary for
mutiple use. Avoid repeated freeze-thaw cycles.
保質期:
The shelf life is related to many factors, storage
state,
buffer ingredients, storage temperature and the stability of the
protein
itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C.
The
shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期:
Delivery time may
differ from different purchasing way or location, please kindly
consult your local distributors for specific delivery time.
Note: All of our
proteins are default shipped with normal blue ice packs, if you
request to ship with dry ice, please communicate with us in
advance
and extra fees will be charged.
注意事項:
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles.; (Microbial infection) Receptor for the C.botulinum neurotoxin type A2 (BoNT/A, botA); glycosylation is not essential but enhances the interaction. Probably also serves as a receptor for the closely related C.botulinum neurotoxin type A1.
基因功能參考文獻:
Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines. PMID: 26339411
SV2A expression in the bladder urothelium increases after BoNT-A injection. PMID: 26241848
the way LEV analogues may interact with SV2A PMID: 25692762
agents that act on the conformation of SV2A might hold great potential in the search for new SV2A-based anticonvulsant therapies PMID: 23530581
The newly identified galactose transport capability of SV2A may have an important role in regulating/modulating synaptic function. PMID: 25326386
The SV2A/FE65 interaction might play a role in synaptic signal transduction. PMID: 24284412
In classical mesial temporal sclerosis 1A, the expression of SV2 isoforms is altered with a marked decrease of SV2A paralleling synaptic loss. PMID: 23617838
High SV2A expression is associated with breast cancer. PMID: 23244111
This study in the German population provides evidence, at a genetic level, for the involvement of the SV2A gene region in schizophrenia. PMID: 23017826
Data report a combined modelling and mutagenesis study that successfully identifies another 11 residues in synaptic vesicle protein 2A that appear to be involved in ligand binding. PMID: 21936812
expression of SV2A in tumor and peritumoral tissue is correlated to the clinical response to levetiracetam and predicts levetiracetam efficacy PMID: 21795655
the role of SV2A in epileptogenesis in patients with glial tumors is questionable PMID: 20167814
We found no association between genetic variation in SV2A and response to levetiracetam or epilepsy predisposition PMID: 18977120
The pattern of SV2A immunoreactivity with reduced neuropil expression and altered cellular and subcellular distribution suggests a possible contribution of SV2A to the epileptogenicity of these malformations of cortical development. PMID: 19220410
Botulinum toxin type A (BTA) inhibits the growth of LNCaP human PCa cells in vitro and in vivo. BTA acts on the cells by virtue of the BTA receptor, the SV2 protein. PMID: 19399787